Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting

Table 3 ATP III Risk Category, Indication for Lipid Lowering Therapy, and Receipt of Therapy (n = 290 patients with lipid results)

	Before EULAR Adjustment		After EULAR Adjustment
Risk Category	N (%)	Indication for therapy based on LDL	N (%)	Indication for therapy after adjustment
Risk Category	N (%)	N (%)	N (%)	N (%)
CHD or CHD Risk Equivalents	92 (32 %)	20 (22 %)	96 (33 %)	23 (24 %)
OR
10 yr risk >20 %
2+ Risk Factors AND	7 (1 %)	1 (50 %)	1 (0.3 %)	0 (0 %)
10-yr risk 10-20 %	7 (1 %)	1 (50 %)	1 (0.3 %)	0 (0 %)
2+ Risk Factors AND	2 (2 %)	0 (0 %)	7 (2 %)	0 (0 %)
10-yr risk <10 %	2 (2 %)	0 (0 %)	7 (2 %)	0 (0 %)
0-1 Risk Factors AND	189 (65 %)	4 (2 %)	186 (64 %)	4 (2 %)
10-yr risk <10 %	189 (65 %)	4 (2 %)	186 (64 %)	4 (2 %)
Total	290 (100 %)	25 (9 %)	290 (100 %)	27 (9 %)

Indication for therapy in each risk category was based on the ATP III guidelines which suggest the following LDL cutoffs: 190 mg/dl for risk category 0, ≥160 mg/dl for risk category 1, and ≥130 mg/dl for risk categories 2 and 3.(15)

ISSN: 1471-2474